First-line treatment of metastatic breast cancer: available evidence and current recommendations

摘要: For many years, tamoxifen was the mainstay of treatment for hormone receptor-positive metastatic breast cancer (MBC). However, in recent newer endocrine agents, particularly aromatase inhibitors, have consistently proved their superiority over by improving clinical outcomes. These agents therefore been incorporated into first-line strategies endocrine-responsive disease. The chemother-apeutic armamentarium has also enriched with new and combinations that played a role survival decades. few chemotherapy trials claimed clear benefit one regimen another. More recently, development biologic further widened spectrum available therapies. Among these, trastuzumab, monoclonal antibody against human epidermal growth factor receptor 2 (HER2), significantly altered lives patients HER2-positive MBC.